NDAORALCAPSULE, EXTENDED RELEASE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PINDAC (pinacidil) is an oral extended-release capsule approved in 1989 as a small-molecule vasodilator. The mechanism of action and specific indications are not documented in available data, limiting characterization of its therapeutic scope. This legacy product operates in a mature market with established standard-of-care alternatives.
LOE Approaching
This product is approaching loss of exclusivity with minimal current commercial infrastructure; career roles are likely focused on optimization and transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PINDAC offers minimal career upside with zero linked job openings and an approaching loss of exclusivity. Professionals should view roles on this product as terminal assignments focused on managed decline rather than career acceleration.
Brand Manager (legacy)Field Sales Representative
Worked on PINDAC at PleoPharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.